Open Accessibility Menu

Sarabjeet "Jeet" Singh, MD

About Sarabjeet "Jeet"

Dr. Sarabjeet "Jeet" Singh pursued his Internal Medicine Residency and Cardiovascular Fellowship at Chicago School of Medicine. Upon finishing Cardiovascular training, he was accepted to Interventional Cardiology Fellowship at Cedars Sinai Medical Center in Los Angeles, CA. Dr. Singh became Board Certified in Interventional Cardiology in 2011 and then shortly thereafter moved to Bakersfield, CA to practice.

Both in Residency and Fellowship, Dr. Singh was selected as a clinical instructor and Chief Cardiology Fellow to guide and mentor Cardiology fellows, Internal Medicine residents, and medical students. He has a passion for managing complex cardiovascular cases and either through performing clinical or surgical intervention he impacts the lives of his patients for the positive. Dr. Singh has published over 30 clinical research studies, authored several book chapters, and has presented his findings at various Cardiovascular Conferences.

Dr. Singh decompresses from his hectic schedule by traveling and spending time with his family. He also understands the importance of maintaining a healthy lifestyle and often spends time at the gym. He brings warmth and laughter to the collegial environment at Central Cardiology Medical Center (CCMC) with his wit and humor.

    Affiliations American College of Physicians, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American Heart Association
    • American Association of Cardiologists of Indian Origin (AACIO) Young Investigator Award

    • Best of Best Sessions, Satellite Symposium, American Heart Association

    • Honorary Degree (M.I.M.S.A.) awarded by International Medical Science Academy

    • Listed in Marquis Who's Who in America

    • Board Certification
    • California License 2010
    • Federal Drug Enforcement Administration, Licensed Practitioner (DEA)
    • College
    • Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.) Calcutta University
    • Fellowship
    • Interventional Cardiology Cedars Sinai Medical Centre and UCLA school of Medicine
      Los Angeles, CA
    • Cardiology Chicago Medical School and affiliated Hospitals
    • Internship
    • Internal Medicine (PGY-1) Chicago Medical School
    • Residency
    • Internal Medicine (PGY1-3) Chowdhary Charan Singh University / L.L.R.M. Medical College and SVBP Hospitals
    • Internal Medicine (PGY-2, 3) Chicago Medical School
    Medical Interests Areas of Interest:

    Interventional Cardiologist specializing in:

    • Coronary Interventions: Diagnostic angiograms, Balloon angioplasty, Stent placement, Rotablation, intravascular ultrasound study (IVUS), Optical coherence tomography (OCT), Fractional Flow reserve study (F.F.R), Placement of balloon pump, Impella device.
    • Structural Intervention: Trained in Transcatheter Aortic Valve Implantation (T.A.V.I.), Balloon aortic valvuloplasty (B.A.V.), Percutaneous Mitral Valvuloplasty (BMV), Mitral clip procedures, Closure of interatrial septal defects including PFO and Atral Septal Defects, Ventricle septal defects (VSD), Left atrial appendage occluder devices , Alcohol septal ablation for Hypertrophic obstructive cardiomyopathy (HOCM)
    • Endovascular Interventions: Carotid stenting, Renal stenting, lower extremity stenting and atherectomy, endovascular Abdominal aortic aneurysmal repair (A.A.A. )
    • Hemodynamic evaluations in cath lab: Oximetry evaluations for shunts, pulmonary hypertensions reversibility evaluations with vasodilator therapies, valve hemodynamics e.t.c.
    • Perform all aspects of exercise and pharmacological stress testing, transthoracic and transesophageal echocardiography, peripheral vascular non-invasive imaging, stress testing and myocardial perfusion imaging, coronary computed cardiovascular tomographic angiography

    1: Sethi A, Bahekar A, Bhuriya R, Singh S, Ahmed A, Khosla S. Complete versus culprit only revascularization in acute ST elevation myocardial infarction: A meta-analysis. Catheter Cardiovasc Interv. 2010 Jun 1. [Epub ahead of print]

    2: Singh S, Singh M, Khosla S. Thrombotic and fibrinolytic factors in acute coronary syndrome. South Med J. 2010 Apr;103(4):282.

    3: Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, Molnar J, Singh S, Khosla S, Arora R. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):158-66. Epub 2010 Mar 5.

    4: Singh M, Singh S, Arora R, Khosla S. Cardiac syndrome X: current concepts. Int J Cardiol. 2010 Jul 9;142(2):113-9. Epub 2010 Feb 7. Review.

    5: Singh PP, Singh M, Bedi US, Adigopula S, Singh S, Kodumuri V, Molnar J, Ahmed A, Arora R, Khosla S. Outcomes of Nonemergent Percutaneous Coronary Intervention With and Without On-site Surgical Backup: A Meta-Analysis. Am J Ther. 2009 Nov 14. [Epub ahead of print]

    6: Singh PP, Arora R, Singh M, Bedi US, Adigopula S, Singh S, Bhuriya R, Molnar J, Khosla S. Safety and efficacy of prolonged use of unfractionated heparin after percutaneous coronary intervention. Am J Ther. 2010 Nov-Dec;17(6):535-42.

    7: Singh S, Duggal J, Khosla N, Arora R. Screening guidelines for coronary heart disease in diabetes: current recommendations. J Cardiometab Syndr. 2009 Spring;4(2):107-12.

    8: Singh S, Bahekar A, Molnar J, Khosla S, Arora R. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol. 2009 Jul;32(7):358-64. Review.

    9: Singh S, Singh M, Pahwa H, Jawad E, Khosla S, Arora R. Prasugrel: a novel antiplatelet therapy for acute coronary syndromes. Recent Pat Cardiovasc Drug Discov. 2009 Nov;4(3):192-202. Review.

    10: Singh S, Arora R, Handa K, Khraisat A, Nagajothi N, Molnar J, Khosla S. Stem cells improve left ventricular function in acute myocardial infarction. Clin Cardiol. 2009 Apr;32(4):176-80. Review.

    11: Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther. 2008 Nov-Dec;15(6):506-11.

    12: Singh S, Khosla S, Gupta V. The role of drug-eluting stents in treating cardiac transplant vasculopathy. South Med J. 2008 Dec;101(12):1198-9.

    13: Singh S, Arora R, Khosla S. Myocardial bridging. South Med J. 2008 Mar;101(3):233-4.

    14: Singh S, Grewal PD, Symons J, Ahmed A, Khosla S, Arora R. Adult-onset dysphagia lusoria secondary to a dissecting aberrant right subclavian artery associated with type B acute aortic dissection. Can J Cardiol. 2008 Jan;24(1):63-5.

    15: Singh S, Arora R, Khraisat A, Handa K, Bahekar A, Trivedi A, Khosla S. Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. J Cardiovasc Pharmacol Ther. 2007 Dec;12(4):298-303. Review.

    16: Singh S, Molnar J, Arora R. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovasc Pharmacol Ther. 2007 Dec;12(4):283-91.

    17: Singh S, Trivedi A, Adhikari T, Molnar J, Arora R, Khosla S. ? Cocaine-related acute aortic dissection: patient demographics and clinical outcomes. Can J Cardiol. 2007 Dec;23(14):1131-4.

    18: Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J. 2007 Nov;154(5):830-7. Epub 2007 Aug 20. Review.

    19: Khraisat A, Singh S, Arora R, Al-Jaghbeer E. A heart aflutter. Am J Med. 2007 Oct;120(10):857-9.

    20: Duggal J, Singh S, Barsano CP, Arora R. Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management. J Cardiometab Syndr. 2007 ummer;2(3):198-206. Review.

    21: Singh S, Verma M, Bahekar A, Agrawal P, Duggal J, Iliescu M, Khosla P, Muzaffar S. Enoxaparin-induced skin necrosis: a fatal outcome. Am J Ther. 2007 Jul-Aug;14(4):408-10.

    22: Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol. 2008 Mar 28;125(1):41-8. Epub 2007 Apr 16.

    23: Singh S, Bembi V, Goel VK, Bedi US, Arora R. Baseline electrocardiographic changes as determinants in the prognosis of cerebrovascular accidents. South Med J. 2006 Dec;99(12):1407-8.

    24: Duggal J, Singh S, Kuchinic P, Butler P, Arora R. Utility of esmolol in thyroid crisis. Can J Clin Pharmacol. 2006 Fall;13(3):e292-5. Epub 2006 Nov 26. 25: Bembi V, Singh S, Singh P, Aneja GK, Arya TV, Arora R. Prevalence of peripheral arterial disease in a cohort of diabetic patients. South Med J. 2006 Jun;99(6):564-9.

    26: Bedi US, Singh S, Syed A, Aryafar H, Arora R. Coronary artery disease in South Asians: an emerging risk group. Cardiol Rev. 2006 Mar-Apr;14(2):74-80. Review.

    27. Bahekar A, Singh M, Singh S, Bhuriya R, Ahmad K, Khosla S, Arora R. Cardiovascular Outcomes Using Intra-Aortic Balloon Pump in High-Risk Acute Myocardial Infarction With or Without Cardiogenic Shock: A Meta-Analysis. J Cardiovasc Pharmacol Ther. 2011 Feb 18.

    28. Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, S?ngh S, Khosla S. Tirofiban

    Use With Clopidogrel and Aspirin Decreases Adverse Cardiovascular Events After

    Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: A

    Meta-analysis of Randomized Trials. Can J Cardiol. 2011 Aug 24.

    29. Singh S, Kashif M, Makkar R.R., Forrester J.S. New Directions in Cardiac Stem Cell Therapy: An Update for Clinicians. International Journal of Cardiology (I.J.C.)

    30.Sharma S, Singh S, Sandhu R, Monterroso M, Bhambi N, Sharma R. Case report series of left atrial thrombus formation in patients on dabigatran therapy. Accepted for Publication in American Journal of Therapeutics (A.J.T.)

    31. Sharma S, Singh S, Lardizabal J.A, Bhambi B. Intra-graft Abciximab and Verapamil Combined with Direct Stenting Prevents Slow-Flow and No-Reflow Phenomenon and can be used as an alternative distal embolic protection strategy in Saphenous Vein Graft lesions not associated with thrombus. Accepted for Publication in Recent Patents on Cardiovascular Drug Discovery.


    1: Singh S, Thapa B, Prabhu R, Arora R, Khosla S. (2008). Angiotensin-Converting Enzyme Inhibitors in Patients with Bilateral Atherosclerotic Renal Artery Steno?is. In Anne N. DeBrue (Ed.), Angiotensin Converting Enzyme Inhibitors (pp. unknown). New York, NY. Nova Publishers.Pg 147-161.

    2. Singh. M., Singh. S., Walia. R., Arora. R., Khosla. S. (2008). Relevance of Antiplatelet Drug Resistance in the Contemporary Era of Percutaneous Coronary Interventions. In Kevin G. Layton and Raymond A. Percelle (Ed.), Angioplasty Research Progress. New York, NY. Novapublishers. Pg 473-492.

    3. Singh. M., Singh. S., Arora. R., Khosla. S. (2008). Percutaneous Interventions in Adult Congenital Heart Diseases. Advances in Cardiovascular Research, Volume 1. In Lukas Schmitt and Timm Knig (Ed.), New York, NY. Novapublishers. Pg 343-366